Clinical use of pasireotide for Cushing’s disease in adults

References

• NiemanLKBillerBMFindlingJWThe diagnosis of Cushing’s syndrome: an Endocrine Society Clinical Practice GuidelineJ Clin Endocrinol Metab20089351526154018334580
   PubMed Web of Science ®Google Scholar
• ColaoABoscaroMFeroneDCasanuevaFFManaging Cushing’s disease: the state of the artEndocrine201447192024415169
   PubMed Web of Science ®Google Scholar
• ChiodiniIMasciaMLMuscarellaSSubclinical hypercortisolism among outpatients referred for osteoporosisAnn Intern Med2007147854154817938392
   PubMed Web of Science ®Google Scholar
• TerzoloMReimondoGChiodiniIScreening of Cushing’s syndrome in outpatients with type 2 diabetes: results of a prospective multicentric study in ItalyJ Clin Endocrinol Metab201297103467347522767639
   PubMed Web of Science ®Google Scholar
• CeccatoFAntonelliGBarbotMThe diagnostic performance of urinary free cortisol is better than the cortisol:cortisone ratio in detecting de novo Cushing’s syndrome: the use of a LC–MS/MS method in routine clinical practiceEur J Endocrinol201417111724743401
   PubMed Web of Science ®Google Scholar
• CeccatoFBarbotMZilioMPerformance of salivary cortisol in the diagnosis of Cushing’s syndrome, adrenal incidentaloma, and adrenal insufficiencyEur J Endocrinol20131691313623610124
   PubMed Web of Science ®Google Scholar
• BoscaroMArnaldiGApproach to the patient with possible Cushing’s syndromeJ Clin Endocrinol Metab20099493121313119734443
   PubMed Web of Science ®Google Scholar
• ColaoADe BlockCGaztambideMSKumarSSeufertJCasanuevaFFManaging hyperglycemia in patients with Cushing’s disease treated with pasireotide: medical expert recommendationsPituitary201417218018623564338
   PubMed Web of Science ®Google Scholar
• ColaoAPetersennSNewell-PriceJPasireotide B2305 Study GroupA 12-month phase 3 study of pasireotide in Cushing’s diseaseN Engl J Med20123661091492422397653
   PubMed Web of Science ®Google Scholar
• DimopoulouCSchopohlJRachingerWLong-term remission and recurrence rates after first and second transsphenoidal surgery for Cushing’s disease: care reality in the Munich Metropolitan RegionEur J Endocrinol2014170228329224217937
   PubMed Web of Science ®Google Scholar
• BarbotMAlbigerNKoutroumpiSPredicting late recurrence in surgically treated patients with Cushing’s diseaseClin Endocrinol (Oxf)201379339440123278711
   PubMed Web of Science ®Google Scholar
• NiemanLKUpdate in the medical therapy of Cushing’s diseaseCurr Opin Endocrinol Diabetes Obes201320433033423807605
   PubMedGoogle Scholar
• GadelhaMRVieira NetoLEfficacy of medical treatment in Cushing’s disease: a systematic reviewClin Endocrinol (Oxf)201480111224118077
   PubMed Web of Science ®Google Scholar
• DevinJKAllenGSCmelakAJDugganDMBlevinsLSThe efficacy of linear accelerator radiosurgery in the management of patients with Cushing’s diseaseStereotact Funct Neurosurg2004825–625426215665560
   PubMed Web of Science ®Google Scholar
• LosaMPicozziPRedaelliMGLaurenziAMortiniPPituitary radiotherapy for Cushing’s diseaseNeuroendocrinology201092suppl 110711020829629
   PubMedGoogle Scholar
• HusebyeESAllolioBArltWConsensus statement on the diagnosis, treatment and follow-up of patients with primary adrenal insufficiencyJ Intern Med2014275210411524330030
   PubMed Web of Science ®Google Scholar
• BillerBMGrossmanABStewartPMTreatment of adrenocorticotropin-dependent Cushing’s syndrome: a consensus statementJ Clin Endocrinol Metab20089372454246218413427
   PubMed Web of Science ®Google Scholar
• CastinettiFMorangeIJaquetPConte-DevolxBBrueTKetoconazole revisited: a preoperative or postoperative treatment in Cushing’s diseaseEur J Endocrinol20081581919918166822
   PubMed Web of Science ®Google Scholar
• VilarLNavesLAAzevedoMFEffectiveness of cabergoline in monotherapy and combined with ketoconazole in the management of Cushing’s diseasePituitary201013212312919943118
   PubMed Web of Science ®Google Scholar
• KamenickýPDroumaguetCSalenaveSMitotane, metyrapone, and ketoconazole combination therapy as an alternative to rescue adrenalectomy for severe ACTH-dependent Cushing’s syndromeJ Clin Endocrinol Metab20119692796280421752886
   PubMed Web of Science ®Google Scholar
• BarbotMAlbigerNCeccatoFCombination therapy for Cushing’s disease: effectiveness of two schedules of treatment. Should we start with cabergoline or ketoconazole?Pituitary201417210911723468128
   PubMed Web of Science ®Google Scholar
• BertagnaXPivonelloRFleseriuMLCI699, a potent 11β-hydroxylase inhibitor, normalizes urinary cortisol in patients with Cushing’s disease: results from a multicenter, proof-of-concept studyJ Clin Endocrinol Metab20149941375138324423285
   PubMed Web of Science ®Google Scholar
• CastinettiFGuignatLGiraudPKetoconazole in Cushing’s disease: is it worth a try?J Clin Endocrinol Metab20149951623163024471573
   PubMed Web of Science ®Google Scholar
• PivonelloRDe MartinoMCCappabiancaPThe medical treatment of Cushing’s disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgeryJ Clin Endocrinol Metab200994122323018957500
   PubMed Web of Science ®Google Scholar
• GodboutAManavelaMDanilowiczKBeauregardHBrunoODLacroixACabergoline monotherapy in the long-term treatment of Cushing’s diseaseEur J Endocrinol2010163570971620702648
   PubMed Web of Science ®Google Scholar
• Pecori GiraldiFScaroniCArvatEEffect of protracted treatment with rosiglitazone, a PPARgamma agonist, in patients with Cushing’s diseaseClin Endocrinol (Oxf)200664221922416430724
   PubMed Web of Science ®Google Scholar
• OcchiGAlbigerNBerlucchiSPeroxisome proliferator-activated receptor gamma in the human pituitary gland: expression and splicing pattern in adenomas versus normal pituitaryJ Neuroendocrinol200719755255917561883
   PubMed Web of Science ®Google Scholar
• DangCNTrainerPPharmacological management of Cushing’s syndrome: an updateArq Bras Endocrinol Metabol20075181339134818209872
   PubMedGoogle Scholar
• Pecori GiraldiFAmbrogioAGAndrioliMPotential role for retinoic acid in patients with Cushing’s diseaseJ Clin Endocrinol Metab201297103577358322851491
   PubMed Web of Science ®Google Scholar
• OcchiGRegazzoDAlbigerNMActivation of the dopamine receptor type-2 (DRD2) promoter by 9-cis retinoic acid in a cellular model of Cushing’s disease mediates the inhibition of cell proliferation and ACTH secretion without a complete corticotroph-to-melanotroph transdifferentiationEndocrinology201415593538354924926820
   PubMed Web of Science ®Google Scholar
• BoscaroMLudlamWHAtkinsonBTreatment of pituitary-dependent Cushing’s disease with the multireceptor ligand somatostatin analog pasireotide (SOM230): a multicenter, phase II trialJ Clin Endocrinol Metab200994111512218957506
   PubMed Web of Science ®Google Scholar
• BrunsCLewisIBrinerUMeno-TetangGWeckbeckerGSOM230: a novel somatostatin peptidomimetic with broad somatotropin release inhibiting factor (SRIF) receptor binding and a unique antisecretory profileEur J Endocrinol2002146570771611980628
   PubMed Web of Science ®Google Scholar
• Cuevas-RamosDFleseriuMSomatostatin receptor ligands and resistance to treatment in pituitary adenomasJ Mol Endocrinol2014523R223R24024647046
   PubMed Web of Science ®Google Scholar
• GiustinaAChansonPKleinbergDExpert consensus document: A consensus on the medical treatment of acromegalyNat Rev Endocrinol201410424324824566817
   PubMed Web of Science ®Google Scholar
• WolinEMHuKHughesGBouillaudEGiannoneVResendizKHSafety, tolerability, pharmacokinetics, and pharmacodynamics of a long-acting release (LAR) formulation of pasireotide (SOM230) in patients with gastroenteropancreatic neuroendocrine tumors: results from a randomized, multicenter, open-label, phase I studyCancer Chemother Pharmacol201372238739523765178
   PubMed Web of Science ®Google Scholar
• van der HoekJWaaijersMvan KoetsveldPMDistinct functional properties of native somatostatin receptor subtype 5 compared with subtype 2 in the regulation of ACTH release by corticotroph tumor cellsAm J Physiol Endocrinol Metab20052892E278E28715769796
   PubMed Web of Science ®Google Scholar
• GolorGHuKRuffinMA first-in-man study to evaluate the safety, tolerability, and pharmacokinetics of pasireotide (SOM230), a multireceptor-targeted somatostatin analog, in healthy volunteersDrug Des Devel Ther201267179
   PubMed Web of Science ®Google Scholar
• Mackenzie FederJBourdeauIValletteSBeauregardHSte-MarieLGLacroixAPasireotide monotherapy in Cushing’s disease: a single-centre experience with 5-year extension of phase III TrialPituitary Epub20131128
   Web of Science ®Google Scholar
• TrementinoLCardinalettiMConcettoniCMarcelliGBoscaroMArnaldiGUp-to 5-year efficacy of pasireotide in a patient with Cushing’s disease and pre-existing diabetes: literature review and clinical practice considerationsPituitary Epub2014621
   Web of Science ®Google Scholar
• TrementinoLCardinalettiMConcettoniCSalivary cortisol is a useful tool to assess the early response to pasireotide in patients with Cushing’s diseasePituitary Epub2014131
   Web of Science ®Google Scholar
• PivonelloRPetersennSNewell-PriceJPasireotide B2305 Study Group. Pasireotide treatment significantly improves clinical signs and symptoms in patients with Cushing’s disease: results from a Phase III studyClin Endocrinol (Oxf)201481340841724533697
   PubMed Web of Science ®Google Scholar
• BadiaXValassiERosetMWebbSMDisease-specific quality of life evaluation and its determinants in Cushing’s syndrome: what have we learnt?Pituitary201417218719523564339
   PubMed Web of Science ®Google Scholar
• WebbSMBadiaXBarahonaMJEvaluation of health-related quality of life in patients with Cushing’s syndrome with a new questionnaireEur J Endocrinol2008158562363018426820
   PubMed Web of Science ®Google Scholar
• WebbSMWareJEForsytheATreatment effectiveness of pasireotide on health-related quality of life in patients with Cushing’s diseaseEur J Endocrinol20141711899824760537
   PubMed Web of Science ®Google Scholar
• FeeldersRAde BruinCPereiraAMPasireotide alone or with cabergoline and ketoconazole in Cushing’s diseaseN Engl J Med2010362191846184820463350
   PubMed Web of Science ®Google Scholar
• MazziottiGGazzarusoCGiustinaADiabetes in Cushing syndrome: basic and clinical aspectsTrends Endocrinol Metab2011221249950621993190
   PubMed Web of Science ®Google Scholar
• BreitschaftAHuKHermosillo ReséndizKDarsteinCGolorGManagement of hyperglycemia associated with pasireotide (SOM230): healthy volunteer studyDiabetes Res Clin Pract2014103345846524461109
   PubMed Web of Science ®Google Scholar
• InzucchiSEBergenstalRMBuseJBAmerican Diabetes Association (ADA)European Association for the Study of Diabetes (EASD)Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD)Diabetes Care20123561364137922517736
   PubMed Web of Science ®Google Scholar
• PetersennSBollerslevJArafatAMPharmacokinetics, pharmacodynamics, and safety of pasireotide LAR in patients with acromegaly: A randomized, multicenter, open-label, phase I studyJ Clin Pharmacol201454111308131724800725
   PubMed Web of Science ®Google Scholar
• DietrichHHuKRuffinMSafety, tolerability, and pharmacokinetics of a single dose of pasireotide long-acting release in healthy volunteers: a single-center Phase I studyEur J Endocrinol2012166582182822383336
   PubMed Web of Science ®Google Scholar